Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2024-01-30 Director's Dealing
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-01-30 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Notification of major holdings' form, which is a standard regulatory filing used in the UK to report when a shareholder's interest in a company crosses specific voting rights thresholds. This falls under the 'Major Shareholding Notification' category (MRQ).
2024-01-30 English
Signing of Strategic Platform License
Regulatory Filings Classification · 1% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service) regarding a strategic platform license agreement between MaxCyte, Inc. and Wugen. It details a business partnership and commercial collaboration rather than a financial report, board change, or legal proceeding. Since it is a general regulatory announcement regarding corporate activity that does not fit into more specific categories like M&A (which usually implies a takeover or merger of the entities themselves) or capital raising, it is classified as a general Regulatory Filing (RNS).
2024-01-30 English
TR-1: Notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Notification of major holdings' form, which is the standard regulatory filing used in the UK to report when a shareholder's interest in a company crosses specific voting rights thresholds. The document explicitly lists BlackRock, Inc. as the entity subject to the notification obligation regarding its holdings in MaxCyte, Inc. This fits the definition of a 'Major Shareholding Notification' (MRQ).
2024-01-29 English
Filing of Form 8-K
Regulatory Filings Classification · 1% confidence The document is a short announcement (under 5,000 characters) from MaxCyte, Inc. regarding the filing of a Form 8-K with the SEC to report the departure of their Chief Scientific Officer. Because the document serves as an announcement of a regulatory filing rather than the filing itself, and specifically mentions the departure of a senior management member, it falls under the category of management changes. However, since the primary purpose of this specific RNS text is to announce the filing of a document (Form 8-K) regarding a management change, it is best classified as a management information announcement.
2024-01-29 English
8-K
Regulatory Filings
2024-01-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.